Skip to main
  1. Stocks
  2. BioMarin Pharmaceutical
  3. Forecast
BMRN

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical (BMRN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 43%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

BioMarin Pharmaceutical is supported by a resilient rare-disease franchise, with mature enzyme therapies generating $2.1B in 2025 and growing at high single-digits, while VOXZOGO is expected to deliver $1B in sales generation in 2026 despite competitor entry. The company also has meaningful near-term operating leverage, as 3Q26 revenue reached $1.025B, operating cash generation was about $188M, and acquired assets such as GALAFOLD and POMBILITI + OPFOLDA added $152M and $49M in their first full quarter under BioMarin. Its outlook is further strengthened by an expanding pipeline, including BMN 333’s 2027 growth update, BMN 440’s 2027 data, and BMN 820’s 2028 readout, which could extend growth beyond the base business.

Bears say

BioMarin Pharmaceutical is viewed cautiously because its growth engine, VOXZOGO, is already showing softening momentum, with 3Q26 revenue of $245M, ~85% U.S. retention, and a lowered 2026 sales guide of $975M-$1.025B amid shipment timing issues and a daily-injection burden. Competitive pressure is intensifying as BridgeBio’s oral infigratinib has a February 4, 2027 FDA action date before VOXZOGO’s May 30 HCH decision, while management plans to stop U.S. switching disclosure in 4Q26, reducing visibility into erosion. Although the base business and royalties from YUVIWEL help offset some weakness, the 2026 non-GAAP EPS guide was cut to $2.80-$3.10 from $4.90-$5.10, with most of the decline tied to Alesta and BMN 450 deal costs and a relatively light pipeline offering limited near-term upside.

BioMarin Pharmaceutical (BMRN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 43% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioMarin Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

BioMarin Pharmaceutical (BMRN) Analyst Forecast & Price Prediction

Get the latest BioMarin Pharmaceutical (BMRN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BioMarin Pharmaceutical (BMRN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioMarin Pharmaceutical (BMRN) Forecast

Analysts have given BioMarin Pharmaceutical (BMRN) a Buy based on their latest research and market trends.

According to 23 analysts, BioMarin Pharmaceutical (BMRN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioMarin Pharmaceutical (BMRN)


BioMarin Pharmaceutical (BMRN) Analyst Forecast & Price Prediction

Get the latest BioMarin Pharmaceutical (BMRN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BioMarin Pharmaceutical (BMRN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BMRN stock data and trends